Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) ("Ventyx", "Company"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
Ventyx Biosciences, Inc.（納斯達克：VTYX）（「Ventyx」，「公司」）是一家臨床階段的生物製藥公司，專注於推進解決一系列炎症性疾病的新型口服療法，這些疾病在醫學上有重大未滿足的需求。今天，公司高管宣佈將參加以下即將舉行的投資者會議：
-
Event: 2024 Wells Fargo Healthcare Conference
Location: Boston, MA
Date: Wednesday, September 4, 2024
Time: 11:00-11:35 AM ET
- 事件：2024年富國銀行醫療保健大會
地點：馬薩諸塞州波士頓
日期：2024年9月4日星期三
時間：上午11:00-11:35 ET
-
Event: Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, NY
Date: Friday, September 6, 2024
Time: 1:05-1:40 PM ET
- 活動名稱：摩根士丹利第22屆全球醫療保健大會
地點：紐約，紐約州
日期：2024年9月6日，星期五
時間：下午1:05至1:40 ET
A webcast of the presentations will be available in the Investors and News section of the Ventyx website at . A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.
演示會的網絡直播將在Ventyx網站的投資者和新聞欄目中提供。直播重播將在活動結束後不久在該網站上提供，持續30天。
About Ventyx Biosciences
關於Ventyx生物科技
Ventyx is a clinical-stage biopharmaceutical company focused on advancing novel oral therapies for patients living with inflammatory diseases. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift inflammation markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit .
Ventyx是一家臨床前期生物製藥公司，致力於推動針對患有炎症性疾病的患者的新型口服治療方案。我們相信，我們高效發現和開發獨特的藥物候選將使我們能夠通過新型口服療法解決重要的未滿足醫療需求，將炎症市場從注射藥物轉變爲口服藥物。我們目前的研發項目包括針對NLRP3、S1P1R和TYK2的自主發現臨床項目，將我們定位爲外周和神經炎症性疾病口服治療領域的領導者。Ventyx總部位於加利福尼亞州聖迭戈。更多有關Ventyx的信息，請訪問。
Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
IR@ventyxbio.com
投資者關係聯繫人
Patti Bank
董事總經理
ICR Westwicke
（415）513-1284
IR@ventyxbio.com
譯文內容由第三人軟體翻譯。